169 related articles for article (PubMed ID: 36249759)
1. Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study.
Mazzucato M; Minichiello C; Vianello A; Visonà Dalla Pozza L; Toto E; Facchin P
Front Pharmacol; 2022; 13():940010. PubMed ID: 36249759
[No Abstract] [Full Text] [Related]
2. [The impact of the use of treatments not included in the reimbursement classes in the care of rare patients: a real world study.].
Mazzucato M; Minichiello C; Visonà Dalla Pozza L; Vianello A; Toto E; De Lorenzi M; Scroccaro G; Facchin P
Recenti Prog Med; 2022; 113(7):440-450. PubMed ID: 35852080
[TBL] [Abstract][Full Text] [Related]
3. Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.
Mulder J; van Rossum T; Mariz S; Magrelli A; de Boer A; Pasmooij AMG; Stoyanova-Beninska V
Front Oncol; 2021; 11():809035. PubMed ID: 34988030
[TBL] [Abstract][Full Text] [Related]
4. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
[TBL] [Abstract][Full Text] [Related]
5. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
Pijeira Perez Y; Wood E; Hughes DA
Orphanet J Rare Dis; 2023 Nov; 18(1):342. PubMed ID: 37915031
[TBL] [Abstract][Full Text] [Related]
6. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
Choudhury MC; Saberwal G
Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
[TBL] [Abstract][Full Text] [Related]
7. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers AE; Moors EH; van Weely S; de Vrueh RL
Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
[TBL] [Abstract][Full Text] [Related]
8. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
Annemans L; Makady A
Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
[TBL] [Abstract][Full Text] [Related]
9. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe.
Jonker CJ; Bakker E; Kurz X; Plueschke K
Front Pharmacol; 2022; 13():924648. PubMed ID: 35991868
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
11. Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group).
Aartsma-Rus A; Dooms M; Le Cam Y
Front Pharmacol; 2021; 12():744532. PubMed ID: 34975469
[TBL] [Abstract][Full Text] [Related]
12. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
13. Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study.
Gorini F; Santoro M; Pierini A; Mezzasalma L; Baldacci S; Bargagli E; Boncristiano A; Brunetto MR; Cameli P; Cappelli F; Castaman G; Coco B; Donati MA; Guerrini R; Linari S; Murro V; Olivotto I; Parronchi P; Pochiero F; Rossi O; Scappini B; Sodi A; Vannucchi AM; Coi A
Front Pharmacol; 2022; 13():869842. PubMed ID: 35652051
[No Abstract] [Full Text] [Related]
14. Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Cavaller-Bellaubi M; Hughes-Wilson W; Kubinová Š; Van de Casteele M; Van Lente EJ; Degortes E; Pontén J; Eichler HG; Le Cam Y; Boselli S; Bucsics A
Orphanet J Rare Dis; 2023 Jun; 18(1):144. PubMed ID: 37308991
[TBL] [Abstract][Full Text] [Related]
15. Estimating mortality in rare diseases using a population-based registry, 2002 through 2019.
Mazzucato M; Visonà Dalla Pozza L; Minichiello C; Toto E; Vianello A; Facchin P
Orphanet J Rare Dis; 2023 Nov; 18(1):362. PubMed ID: 37978388
[TBL] [Abstract][Full Text] [Related]
16. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
17. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties.
Pontes C; Fontanet JM; Vives R; Sancho A; Gómez-Valent M; Ríos J; Morros R; Martinalbo J; Posch M; Koch A; Roes K; Oude Rengerink K; Torrent-Farnell J; Torres F
Orphanet J Rare Dis; 2018 Nov; 13(1):206. PubMed ID: 30442155
[TBL] [Abstract][Full Text] [Related]
18. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.
Czech M; Baran-Kooiker A; Atikeler K; Demirtshyan M; Gaitova K; Holownia-Voloskova M; Turcu-Stiolica A; Kooiker C; Piniazhko O; Konstandyan N; Zalis'ka O; Sykut-Cegielska J
Front Public Health; 2019; 7():416. PubMed ID: 32117845
[No Abstract] [Full Text] [Related]
19. The Epidemiology of Transition into Adulthood of Rare Diseases Patients: Results from a Population-Based Registry.
Mazzucato M; Visonà Dalla Pozza L; Minichiello C; Manea S; Barbieri S; Toto E; Vianello A; Facchin P
Int J Environ Res Public Health; 2018 Oct; 15(10):. PubMed ID: 30309015
[No Abstract] [Full Text] [Related]
20. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
